Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1

Anticancer Research

Volumn 28, Issue 5 A, 2008, Pages 2721-2725

  Oei, Angèle L M ^a   Sweep, Fred C G J ^a   Geurts Moespot, Anneke ^a   Van Tienoven, Doorlène ^a   Von Mensdorff Pouilly, Silvia ^b   Thomas, Chris M G ^a   Massuger, Leon F A G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HAMA; HMFG1; IgG; IgM; Intraperitoneal; Ovarian cancer

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; HMFG1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTOXINS; MICE; MIDDLE AGED; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 55749102716     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Burchell J and Taylor-Papadimitriou J: Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol 2: 155-162, 1993.
3. Bast RC Jr, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S and Knapp RC: Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68: 1758-1763, 1991.
4. Taylor-Papadimitriou J, Peterson JA, Arklie J, Burchell J, Ceriani RL and Bodmer WF: Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 28: 17-21, 1981.
5. Kosmas C, Epenetos AA and Courtenay-Luck NS: Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 73: 3000-3010, 1994.
6. Nicholson S, Gooden CS, Hird V, Maraveyas A, Mason P, Lambert HE, Meares CF and Epenetos AA: Radioimmuno-therapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep 5: 223-226, 1998.
7. Khazaeli MB, Conry RM and LoBuglio AF: Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 15: 42-52, 1994.
8. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM and DeNardo SJ: Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 55: 1451-1458, 2006.
9. Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI and Canevari S: Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 84: 62-68, 1999.
10. Mobus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, Schultes BC and Nicodemus CF: Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 189: 28-36, 2003.
11. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T, Stamp G, Spiegel G, Thurston D, Falke T, Lambert J and Seiden MV: Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 24: 571-578, 2006.
12. Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, Epenetos AA and Massuger LF: Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFGl without improvement in overall survival. Int J Cancer 120: 2710-2714, 2007.
13. Oei AL, Boerman OC, Geurts-Moespot A, van Eerd JE, van TD, Courtenay-Luck N, Thomas CM, Massuger LF and Sweep FC: Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodies. Int J Biol Markers 22: 167-171, 2007.
14. Cox DR: Regression models and life tables. J R Stat Soc B34: 187-220, 1972.
15. Epenetos AA, Hird V, Lambert H, Mason P and Coulter C: Longterm survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10: 44-46, 2000.
16. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JS, Mason P, Lambert HE and Epenetos AA: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68: 403-406, 1993.
17. Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, Papadimitriou JT, Rowlinson G, Sullivan M and Lambert HE: Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 8: 1941-1950, 1990.
18. Kosmas C, Epenetos AA and Courtenay-Luck NS: Patients receiving murine monoclonal antibody therapy for malignancy develop T-cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer 64: 494-500, 1991.
19. Schultes BC, Baum RP, Niesen A, Noujaim AA and Madiyalakan R: Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother 46: 201-212, 1998.
20. Wagner U, Schlebusch H, Kohler S, Schmolling J, Grunn U and Krebs D: Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 16: 33-40, 1997.
21. Roitt I, Brostoff J and Male D: Immunology. Chapter 11 Cell cooperation in the antibody response. London, Mosby International Ltd, UK, pp. 139-153, 1998.
22. Donnerstag B, Baum RP, Oltrogge JB, Hertel A and Hor G: A preliminary study on the functional analysis of peripheral blood lymphocytes from ovarian cancer patients developing HAMA after immunoscintigraphy. Int J Biol Markers 9: 115-120, 1994.
23. Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP and Ketterer N: Long-term complete responses after 1311-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 94: 1770-1776, 2006.
24. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, Jr., Rivkin S, Schultes BC, Whiteside TL and Nicodemus CF: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22: 3507-3516, 2004.
25. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC and Swenerton KD: A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15: 1023-1034, 2005.